ALX ONCOLOGY HOLDINGS INC Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 16.03 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 16.03M shares, a 20.74% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 16.37M shares, a 27.88% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 11.98M shares, a 4.26% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 13.27M shares, a 14.80% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 13.18M shares, a 11.81% increase from fiscal 2024.
- ALX ONCOLOGY HOLDINGS INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 11.79M shares, a 18.63% increase from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 9.93M shares, a 41.57% increase from fiscal 2022.
- ALX ONCOLOGY HOLDINGS INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 7.02M shares, a 36.42% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 16.03M shares 10-Q · filed 2026-08-06 | 16.03M shares 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 16.37M shares 10-Q · filed 2026-05-08 | ||||
| 2025-12-31 | 13.18M shares 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | 11.98M shares 10-Q · filed 2025-11-07 | 11.98M shares 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | 13.27M shares 10-Q · filed 2026-08-06 | 13.27M shares 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 12.80M shares 10-Q · filed 2026-05-08 | ||||
| 2024-12-31 | 11.79M shares 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | 11.49M shares 10-Q · filed 2025-11-07 | 11.49M shares 10-Q · filed 2025-11-07 | |||
| 2024-06-30 | 11.56M shares 10-Q · filed 2025-08-12 | 11.56M shares 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | 11.50M shares 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | 9.93M shares 10-K · filed 2026-03-09 | ||||
| 2023-09-30 | 10.20M shares 10-Q · filed 2024-11-07 | 10.20M shares 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 7.36M shares 10-Q · filed 2024-08-12 | 7.36M shares 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | 7.32M shares 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | 7.02M shares 10-K · filed 2025-03-06 | ||||
| 2022-09-30 | 7.11M shares 10-Q · filed 2023-11-13 | 7.11M shares 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | 5.72M shares 10-Q · filed 2023-08-10 | 5.72M shares 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | 5.46M shares 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | 5.14M shares 10-K · filed 2024-03-07 | ||||
| 2021-09-30 | 4.91M shares 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | 4.42M shares 10-Q · filed 2022-08-08 | ||||
| 2021-03-31 | 4.35M shares 10-Q · filed 2022-05-09 | ||||
| 2020-12-31 | 4.86M shares 10-K · filed 2023-03-09 | ||||
| 2020-09-30 | 4.75M shares 10-Q · filed 2020-11-12 | 25.31M shares 10-Q · filed 2021-11-12 | 4.75M shares 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | 25.31M shares 10-Q · filed 2021-08-12 | ||||
| 2020-03-31 | 24.65M shares 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | 11.59M shares 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | 11.57M shares 10-Q · filed 2020-11-12 | 11.57M shares 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | 11.31M shares 10-Q · filed 2020-08-27 | ||||
| 2018-12-31 | 10.39M shares 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |